Suven Pharmaceuticals Limited
Suven Pharmaceuticals Limited, a prominent player in the pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1989, the company has established itself as a leader in the development of innovative drug discovery and development services, particularly in the fields of central nervous system disorders and other therapeutic areas. With a strong focus on research and development, Suven Pharmaceuticals offers a diverse portfolio of products, including proprietary drug candidates and contract research services. The company is recognised for its unique approach to drug development, leveraging advanced technologies to enhance therapeutic efficacy. Suven's commitment to quality and innovation has positioned it favourably in the global market, earning accolades for its contributions to healthcare and significant milestones in clinical research. As it continues to expand its operational footprint, Suven Pharmaceuticals remains dedicated to improving patient outcomes through cutting-edge pharmaceutical solutions.
DitchCarbon Score
How does Suven Pharmaceuticals Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Suven Pharmaceuticals Limited's score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Suven Pharmaceuticals Limited's reported carbon emissions
In 2024, Suven Pharmaceuticals Limited reported total carbon emissions of approximately 41,183,000 kg CO2e for Scope 1 and about 22,941,000 kg CO2e for Scope 2. This represents a slight decrease from 2023, where emissions were approximately 48,594,000 kg CO2e for Scope 1 and about 33,723,000 kg CO2e for Scope 2. The company has set ambitious climate commitments, aiming for a 15% reduction in CO2 emissions per metric ton produced for both Scope 1 and Scope 2 by 2025, starting from a 2023 baseline. Long-term targets include a significant reduction of 90% in absolute Scope 1 and Scope 2 emissions by 2050, also from a 2023 base year. Additionally, Suven Pharmaceuticals has committed to reducing absolute Scope 3 emissions by 90% within the same timeframe. Near-term targets for Scope 1 and 2 emissions also include a 54.6% reduction by 2033. These targets align with the Science Based Targets initiative (SBTi) and are designed to keep global warming below 1.5°C. The company is on track to meet its near-term goals, demonstrating a proactive approach to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 47,497,790 | 00,000,000 | 00,000,000 |
| Scope 2 | 35,462,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Suven Pharmaceuticals Limited is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
